E76.1 Mucopolysaccharidosis, type II

Name of the Condition

• Mucopolysaccharidosis, type II (ICD-10 Code: E76.1)

Summary

Mucopolysaccharidosis, type II (MPS II) is a rare inherited disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans (GAGs) in tissues. This buildup disrupts normal cellular function, resulting in progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early diagnosis and intervention are critical to manage symptoms and slow disease progression.

Causes

MPS II is caused by genetic mutations in the IDS gene, which encodes the iduronate-2-sulfatase enzyme. These mutations impair the enzyme's ability to break down GAGs, leading to their accumulation in cells, tissues, and organs. The condition follows an X-linked recessive inheritance pattern, meaning males are typically more severely affected, while females may be carriers or show variable symptoms.

Risk Factors

• Family history of MPS II or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for IDS mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, and hearing loss.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, enzyme activity testing (iduronate-2-sulfatase deficiency), and genetic testing to confirm mutations in the IDS gene. Urine tests may show elevated GAG levels, and imaging studies can assess organ and skeletal involvement.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Enzyme replacement therapy (ERT) is available to address systemic manifestations. Supportive care includes physical therapy, surgery for skeletal or organ complications, and management of neurological symptoms.

Prognosis and Follow-Up

Prognosis varies based on disease severity and age of onset. Early intervention improves outcomes, but progressive organ damage and neurological decline may occur. Regular follow-up with specialists (e.g., geneticists, neurologists) is essential to monitor complications and adjust care.

Complications

• Progressive neurological impairment (e.g., cognitive decline, motor dysfunction).
• Respiratory and cardiac complications due to organ enlargement.
• Skeletal deformities and joint contractures.
• Vision and hearing loss.

Lifestyle & Prevention

• Genetic counseling for families with a history of MPS II.
• Prenatal testing or carrier screening for at-risk pregnancies.
• Supportive therapies (e.g., physical therapy) to maintain mobility and function.

When to Seek Professional Help

Seek medical attention if symptoms such as developmental delays, organ enlargement, or skeletal abnormalities are observed, especially in males with a family history of the condition.

Tips for Medical Coders

Document the specific type of mucopolysaccharidosis (type II) and confirm the presence of characteristic symptoms or diagnostic findings. Ensure the code E76.1 is used for confirmed cases, with additional codes for complications or associated conditions as needed.